AMRX vs ED · P/E 44, rev $2.79B vs P/E 18, rev $15.26B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Consolidated Edison Inc (ED) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Consolidated Edison Inc (ED) is a utilities - regulated electric company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported ED revenue for 2024-12-31 was $15.26B. Net income was $1.82B. Revenue was up 4.0% from 2023-12-31 to 2024-12-31. ED currently screens at market cap $36.02B and trailing P/E 18.3.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. ED currently screens at market cap $36.02B and trailing P/E 18.3.
Not investment advice. Open the AMRX and ED stock pages for the full models.
Not investment advice.